| Authors: |
Shimony S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Shai_shimony@dfci.harvard.edu., Raman HS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Flamand Y; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA., Keating J; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA., Paolino JD; Department of Pediatric Oncology, Dana Farber Cancer Institute & Boston Children's Hospital, Boston, MA, USA., Valtis YK; Memorial Sloan Kettering Cancer Institute, New York, NY, USA., Place AE; Department of Pediatric Oncology, Dana Farber Cancer Institute & Boston Children's Hospital, Boston, MA, USA., Silverman LB; Department of Pediatric Oncology, Dana Farber Cancer Institute & Boston Children's Hospital, Boston, MA, USA., Sallan SE; Department of Pediatric Oncology, Dana Farber Cancer Institute & Boston Children's Hospital, Boston, MA, USA., Vrooman LM; Department of Pediatric Oncology, Dana Farber Cancer Institute & Boston Children's Hospital, Boston, MA, USA., Brunner AM; Leukemia Program, Massachusetts General Hospital, Boston, MA, USA., Neuberg DS; Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA., Galinsky I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Winer ES; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wadleigh M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Connors JM; Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Luskin MR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. |
